Sanofi/GSK restart COVID-19 vaccine trials after tweaking formulation
pharmaphorum
FEBRUARY 22, 2021
In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults. At the time analysts said that this was likely due to an insufficient concentration of the antigen and the companies have refined their antigen formulation hoping for a better immune response including in older adults.
89 
Let's personalize your content